Is a Generic Version of Exparel Approved?
As of late 2023, there is no FDA-approved generic version of Exparel. Exparel, known generically as liposomal bupivacaine, is an extended-release local anesthetic used for post-operative pain management [1].
When Can Generic Exparel Be Approved?
The timeline for generic approval of Exparel is tied to the expiration of its patents and market exclusivity. DrugPatentWatch.com tracks these patent expiries. While specific patent details can be complex and subject to legal challenges, generally, the earliest a generic could be approved is after the expiration of relevant patents and any granted exclusivity periods [2].
What Are the Patent Expiries for Exparel?
Pacira Pharmaceuticals, the manufacturer of Exparel, holds several patents protecting the drug. DrugPatentWatch.com lists these patents and their expiry dates, which are crucial for determining when generic competition might emerge. For instance, U.S. Patent No. 11,554,080 for Exparel is set to expire in 2038 [3]. Other patents may offer protection for different aspects of the drug or its use.
Who Are the Potential Competitors for Generic Exparel?
Once patents expire and regulatory hurdles are cleared, pharmaceutical companies specializing in generic drug manufacturing would be eligible to seek FDA approval for their versions of liposomal bupivacaine. Identifying specific competitors at this stage is speculative, as it depends on a company's research and development pipeline and strategic interests in the pain management market [2].
What is the Difference Between Exparel and Generic Versions?
The primary difference between branded Exparel and a future generic version would be the manufacturer and, consequently, the brand name. A generic drug, to be approved by the FDA, must demonstrate bioequivalence to the branded product, meaning it contains the same active ingredient in the same strength and is expected to produce the same clinical effect. Differences might arise in inactive ingredients, which are not expected to affect safety or efficacy [1].
What is the Clinical Data for Liposomal Bupivacaine?
Clinical trials for liposomal bupivacaine, the active ingredient in Exparel, have demonstrated its efficacy in providing prolonged analgesia after various surgical procedures, such as orthopedic surgeries, abdominal procedures, and breast surgeries. The drug's unique liposomal formulation allows for a slower release of bupivacaine from the injection site, extending its duration of action compared to standard bupivacaine injections [1].
What Are the Risks Associated with Exparel?
Like all medications, Exparel carries potential risks and side effects. Common side effects include nausea, constipation, headache, and fever. More serious risks, though rare, can involve allergic reactions and neurological side effects, particularly if injected into a blood vessel. Patients should discuss their medical history and any concerns with their healthcare provider before receiving Exparel [1].
How Does Exparel Pricing Compare to Other Pain Management Options?
Branded Exparel is a premium-priced medication. The introduction of generic alternatives typically leads to a significant reduction in drug costs. The pricing of future generic liposomal bupivacaine would likely be considerably lower than current Exparel prices, making extended-release local anesthesia more accessible. This price difference is a major driver for the development and adoption of generics [2].
***
Sources:
[1] https://www.exparel.com/
[2] https://drugpatentwatch.com/
[3] https://drugpatentwatch.com/p/patents/US11554080B2/pacira-pharmaceuticals-inc/11554080